Matthew H. Taylor

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

Michael A. Postow, Jason Chesney, Anna C. Pavlick et al. · New England Journal of Medicine · 2015 · 2.8K citations · Full text

Life Sciences, Immunology, Oncology +17

Efficacy of Larotrectinib in <i>TRK</i> Fusion–Positive Cancers in Adults and Children

Alexander Drilon, Theodore W. Laetsch, Shivaani Kummar et al. · New England Journal of Medicine · 2018 · 2.7K citations · Full text

Medicine, Oncology, Pharmacology +16

Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer

Martin Schlumberger, Makoto Tahara, Lori J. Wirth et al. · New England Journal of Medicine · 2015 · 2.1K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

Scott Antonia, José A. López-Martín, Johanna C. Bendell et al. · The Lancet Oncology · 2016 · 1.3K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +14

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

F. Stephen Hodi, Jason Chesney, Anna C. Pavlick et al. · The Lancet Oncology · 2016 · 980 citations

Medicine, Immunology, Oncology +17